Wednesday, Nov 18, 2026
English News
  • Hyderabad
  • Telangana
  • AP News
  • India
  • World
  • Entertainment
  • Sport
  • Science and Tech
  • Business
  • Rewind
  • ...
    • NRI
    • View Point
    • cartoon
    • My Space
    • Education Today
    • Reviews
    • Property
    • Lifestyle
E-Paper
  • NRI
  • View Point
  • cartoon
  • My Space
  • Reviews
  • Education Today
  • Property
  • Lifestyle
Home | India | Covaxin Has Ability To Neutralise Uk Strain Of Covid 19 Review Report

Covaxin has ability to neutralise UK strain of COVID-19: Review report

Covaxin is India's totally indigenous COVID-19 vaccine developed in collaboration with the Indian Council of Medical Research and National Institute of Virology.

By PTI
Updated On - 28 January 2021, 01:10 AM
Covaxin has ability to neutralise UK strain of COVID-19: Review report
whatsapp facebook twitter telegram

Hyderabad: Covaxin, developed by Bharat Biotech, has the ability to neutralise the UK variant of the coronavirus, according to a preprint review by bioRxiv, a free online archive and distribution service for unpublished preprints in the life sciences.

The archive is operated by Cold Spring Harbor Laboratory, a not-for-profit research and educational institution in New York.


Bharat Biotech performed the plaque reduction neutralisation test (PRNT50) using sera collected from the 26 recipients of Covaxin and tested them against the UK variant and heterologous strain, the report said.

“A comparable neutralisation activity of sera of the vaccinated individuals showed against UK-variant and the heterologous strain with similar efficiency, dispel the uncertainty of possible neutralisation escape,” the preprint review published in bioRxivs website said.

Covaxin is India’s totally indigenous COVID-19 vaccine developed in collaboration with the Indian Council of Medical Research and National Institute of Virology.

It is developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3) bio-containment facility, one of its kind in the world.

The vaccine is currently under Phase-3 trials and is being used as part of the nationwide immunisation programme for healthcare workers after the Central Licensing Authority granted permission for the sale or distribution of Covaxin for restricted use in emergency situations.

Reacting to the bioRxiv review, ICMR tweeted “COVAXIN developed by @BharatBiotech with @ICMRDELHI has equivalent immunogenicity against the UK-variant & circulating strains of SARS-COV-2 in India. @icmr_niv is the first in the world to culture the UK variant.”

COVAXIN developed by @BharatBiotech with @ICMRDELHI has equivalent immunogenicity against the UK-variant & circulating strains of SARS-COV-2 in India.@icmr_niv is the first in the world to culture the UK variant. Read more: https://t.co/HfhH8z6T8x / J Travel Med (In Press) pic.twitter.com/cGp537bi0H

— ICMR (@ICMRDELHI) January 27, 2021

Join Our Whatsapp Channel
  • Follow Us :
As preferred source
  • Tags
  • Bharat Biotech
  • Coronavirus
  • Covaxin
  • Covid-19

Related News

  • Bharat Biotech announces 40 pc price cut for Mosqivac malaria vaccine

    Bharat Biotech announces 40 pc price cut for Mosqivac malaria vaccine

  • Harish asks BRSV to highlight govt’s failure to release fee reimbursement funds

    Harish asks BRSV to highlight govt’s failure to release fee reimbursement funds

  • Opinion: The next coronavirus will be AI-designed

    Opinion: The next coronavirus will be AI-designed

  • Odisha reports two new COVID-19 cases, total infections rise to three

    Odisha reports two new COVID-19 cases, total infections rise to three

Latest News

  • Man allegedly tied up and set ablaze on Bengaluru road in broad daylight

    8 minutes ago
  • Apple restores most services after internal software update triggers outage; rules out cyberattack

    29 minutes ago
  • Microsoft unveils AI models, Copilot platform and Azure upgrades at Ignite

    46 minutes ago
  • KTR launches ‘Game Changers’ book chronicling journeys of 20 everyday heroes

    54 minutes ago
  • Chip curbs, mineral supplies test Trump’s China diplomacy ahead of Xi talks

    1 hour ago
  • Dhanush thanks Dhoni after CSK exit as player, says game will never be the same

    1 hour ago
  • Fire destroys furniture shop in Shankarpally; no casualties reported

    2 hours ago
  • Sensex falls 370 points, Nifty drops below 25,250 amid profit-taking

    2 hours ago

company

  • Home
  • About Us
  • Contact Us
  • Privacy Policy

business

  • Subscribe

telangana today

  • Telangana
  • Hyderabad
  • Latest News
  • Entertainment
  • World
  • Andhra Pradesh
  • Science & Tech
  • Sport

follow us

  • Telangana Today Telangana Today
Telangana Today Telangana Today

© Copyrights 2024 TELANGANA PUBLICATIONS PVT. LTD. All rights reserved. Powered by Veegam

Telangana Today App